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ABSTRACT
Because of the potent graft-versus-tumor (GVT) effect, allogeneic stem cell transplantation (alloSCT) can be
a curative therapy for hematological malignancies. However, relapse remains the most frequent cause of
treatment failure, illustrating the necessity for development of adjuvant post-transplant therapies to boost
GVT immunity. Dendritic cell (DC) vaccination is a promising strategy in this respect, in particular, where
distinct biologic functions of naturally occurring DC subsets, i.e. myeloid DCs (mDCs) and plasmacytoid
DCs (pDCs), are harnessed. However, it is challenging to obtain high enough numbers of primary DC
subsets from blood for immunotherapy due to their low frequencies. Therefore, we present here an ex vivo
GMP-compliant cell culture protocol for generating different DC subsets from CD34C hematopoietic stem
and progenitor cells (HSPCs) of alloSCT donor origin. High numbers of BDCA1C mDCs and pDCs could be
generated, sufﬁcient for multiple vaccination cycles. These HSPC-derived DC subsets were highly potent in
inducing antitumor immune responses in vitro. Notably, HSPC-derived BDCA1C mDCs were superior in
eliciting T cell responses. They efﬁciently primed na€ıve T cells and robustly expanded patient-derived
minor histocompatibility antigen (MiHA)-speciﬁc T cells. Though the HSPC-pDCs also efﬁciently induced T
cell responses, they exhibited superior capacity in activating NK cells. pDC-primed NK cells highly
upregulated TRAIL and possessed strong cytolytic capacity against tumor cells. Collectively, these ﬁndings
indicate that HSPC-derived DC vaccines, comprising both mDCs and pDCs, may possess superior potential
to boost antitumor immunity post alloSCT, due to their exceptional T cell and NK cell stimulatory capacity.
Abbreviations: AA, Ascorbic acid; AlloSCT, Allogeneic stem cell transplantation; CTL, Cytotoxic T lymphocyte; DC,
Dendritic cell; GMP, Good Manufacturing Practice; GVHD, Graft-vs.-host disease; GVT, Graft-vs.-tumor; HS, Human
serum; HSPC, Hematopoietic stem and progenitor cell; HSPC-DC, HSPC-derived DC; IFN, Interferon; IL, Interleukin;
MiHA, Minor histocompatibility antigen; mDC, Myeloid DC; MoDC, Monocyte-derived DC; PBMC, Peripheral blood
mononuclear cell; pDC, Plasmacytoid DC; Poly I:C, Polyinosinic:polycytidylic acid; RPI:C, R848 C Poly I:C; SR1, Stem-
Regenin 1; TLR, Toll-like receptor.
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Introduction
Allogeneic stem cell transplantation (alloSCT) can be a curative
treatment of patients with hematological malignancies. The thera-
peutic effect, the so called graft-versus-tumor (GVT) effect, can be
attributed to donor-derived CD8C T cells directed against antigens
expressed on the recipient tumor cells, including minor histocom-
patibility antigens (MiHAs) and tumor-associated antigens
(TAAs).1,2 In addition, multiple reports demonstrate that NK cells
also contribute to GVT immunity, as a high number of NK cells in
stem cell grafts,3 as well as early NK cell repopulation,4,5 have been
associated with reduced relapse rates. Still, tumor relapse remains a
leading cause of treatment failure, illustrating the necessity to
develop potent adjuvant post-transplant immunotherapies to boost
GVT immunity, and improve clinical outcome after alloSCT.
Dendritic cell (DC) vaccination is an attractive approach to
induce and boost GVT responses, as DCs are the most powerful
antigen-presenting cells.6,7 Exploiting DC vaccines, T cell
responses directed against hematopoietic-restricted MiHAs
or TAAs can be speciﬁcally boosted, thereby enhancing
GVT activity without evoking potentially life-threatening
graft-versus-host-disease (GVHD). In vivo, multiple blood DC
subsets exist, each with their distinct phenotypic and functional
characteristics.8,9 These subsets can broadly be divided into two
groups, myeloid and plasmacytoid DCs (mDCs and pDCs,
respectively), where mDCs can be further subdivided into
BDCA1C mDCs and BDCA3C mDCs.10 mDCs are in the front
line of defense against fungi and bacteria, which they detect via
different pattern-recognition receptors, including Toll-like
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receptors (TLRs). They possess high antigen processing and
presenting capacity and secrete interleukin (IL)-12, which
makes them highly effective in promoting proinﬂammatory
interferon (IFN)-g secreting T helper (Th)-1 and cytotoxic T
lymphocyte (CTL) responses.8,9,11,12 In contrast, pDCs play a
key role in the detection and control of viral infections, primar-
ily due to their specialized production of type I IFN (IFN-a/b)
following TLR7 and TLR9 stimulation.13 Their secretion of
IFN-a provides an immunostimulatory environment for both
innate and adaptive immune cells. Notably, IFN-a and contact-
dependent interactions potentiate DC-mediated activation,
IFN-g secretion and cytolytic capacity of NK cells.14-18 Further-
more, studies have indicated that the different DC subsets act
synergistically via cross-talk, thereby potentiating each others’
stimulatory capacity.19-23 Together, these characteristics render
vaccines composed of both mDCs and pDCs highly attractive
for the induction of broad antitumor immune responses.
Recently, we reported an innovative ex vivo culture pro-
tocol to efﬁciently generate high numbers of functional
BDCA1C mDCs, BDCA3C mDCs and pDCs from CD34C
hematopoietic stem and progenitor cells (HSPCs).24 We dis-
covered that inhibition of the aryl hydrocarbon receptor,
using the antagonist StemRegenin 1 (SR1), was essential for
DC subset differentiation. In this paper, we describe optimi-
zations of this SR1-based culture protocol, where culture
conditions were improved for generation of higher amounts
and better differentiated mDC and pDC subsets. In addi-
tion, culture conditions were adapted to Good Manufactur-
ing Practice (GMP). Notably, this protocol allows the
generation of the different DC subsets from CD34C HSPCs
derived from the original donor grafts. Importantly, we
demonstrated the superior capacity of HSPC-derived mDCs
and pDCs in stimulating tumor-reactive T cells and NK
cells. While the generated mDCs were better T cell stimula-
tors, the cultured pDCs were superior in inducing cytotoxic
NK cell responses. Cumulatively, HSPC-derived DC subset
(HSPC-DC) vaccines hold great promise for future applica-
tion as post-transplant therapy to selectively boost GVT
immunity and improve relapse-free survival.
Results
A GMP-compliant cell culture protocol for generation of
high numbers of BDCA1CmDCs and pDCs from HSPCs
The overall aim of this study was to generate a DC vaccine
composed of both mDC and pDC subsets and to examine its
potential to boost both antitumor T cell and NK cell responses.
The ﬁrst objective was to establish culture conditions compliant
with GMP, where sufﬁcient numbers of well differentiated and
functional DC subsets were generated from HSPCs for eventual
clinical application. Therefore, we ﬁrst modiﬁed our recently
established SR1-based culture protocol, where the different
HSPC-DC subsets were generated under serum-free conditions
in GBGM medium supplemented with FLT3L, SCF, TPO, IL-6
and SR1.24 Our ﬁrst optimization steps were to omit IL-6 from
the cytokine cocktail and to switch to the widely available
GMP-compliant Cellgro DC medium from Cellgenix, supple-
mented with 2% human serum (HS) and ascorbic acid (AA,
50 mg/mL). We observed that IL-6 inhibited in vitro DC differ-
entiation, while AA and HS had a positive effect on DC-genera-
tion (Fig. S1). As mDCs generated with the previously
published protocol showed low CD11c expression and limited
IL-12 secretion upon TLR stimulation,24 we next investigated
whether the HSPC-DC generation protocol would beneﬁt from
an additional mDC-differentiation boost at the end of the cul-
ture. For this purpose, we compared a two-step protocol, where
HSPCs were ﬁrst expanded with Flt3L, SCF and TPO (FST) for
7–13 d and then differentiated for one week in the presence of
GM-CSF and IL-4 (G4 culture), to the standard one-step proto-
col where HSPCs were cultured for 14–20 d in the presence of
FST (FST culture, Fig. 1A). After 14–20 days, FST-cultured cells
had expanded 133-fold in average, while G4-cultured cells
expanded only 82-fold in average (Fig. 1B). The frequencies of
the different DC subsets were determined in both cultures as
depicted in Fig. S2. We observed a signiﬁcant increase in the
frequency of BDCA1C mDCs in G4 cultures compared with
FST cultures, while pDC differentiation and/or survival was sig-
niﬁcantly reduced in G4 cultures (Fig. 1C–D). Nevertheless,
low frequencies of pDCs were still detectable in short-term
expanded G4 cultures, although these pDCs exhibited lower
BDCA2 expression than their FST-cultured counterparts
(Fig. 1C, Fig. S2D). The absolute number of generated BDCA1C
mDCs was similar for FST and G4 cultures, where both proto-
cols resulted in generation of 18 £ 106 BDCA1CmDCs in aver-
age from only 1 £ 106 CD34C HSPCs (Fig. 1E). Notably, the
one-step protocol resulted in almost 10-fold higher absolute
numbers of pDCs, where in average 16£ 106 pDCs were gener-
ated from only 1 £ 106 CD34C HSPCs (Fig. 1E). Although of
low occurrence, BDCA3CDNGR1C mDCs were detected in
both cultures (Fig. 1C–E). Important for clinical implementa-
tion, we observed that cryopreserved/thawed HSPCs performed
equally well in terms of expansion and DC differentiation as
freshly isolated CD34C HSPCs (Fig. S3). Flow cytometric analy-
sis showed that BDCA1C mDCs expressed high HLA-DR in
both cultures, while the expression of CD11c increased upon
G4 culture, suggestive of a more differentiated phenotype
(Fig. 1F–G). Notably, the majority of the BDCA1C mDCs were
negative for the monocytic marker CD14 (Fig. 1F).
Based on these data, we continued with the G4 culture for
the generation of BDCA1C mDCs, and the FST culture for
pDC generation. For further characterization, sorted G4-gener-
ated BDCA1C mDCs and FST-generated pDCs were matured
overnight with TLR-ligands and evaluated for phenotypical
maturation and cytokine secretion. Our previous studies on
SR1-derived HSPC-DCs showed that the HSPC-mDCs express
TLR3, TLR4, TLR7 and TLR8, while the HSPC-pDCs express
TLR7 and TLR9.24 To optimally stimulate BDCA1C mDCs,
we used a combination of the TLR3 agonist Poly I:C and
TLR7/8 agonist R848, as simultaneous stimulation with these
two agents has shown a synergistic effect.25,26 For stimulation
of ex vivo-generated pDCs, we used either R848, which indu-
ces both IFN-a secretion and upregulation of maturation
markers, or the TLR9 agonist CpG-A, known to induce secre-
tion of large amounts of IFN-a.27,28 Importantly, we observed
high IL-12p70 secretion and tumor necrosis factor (TNF)-a
by the matured BDCA1C mDCs (Fig. S4A). Additionally, they
upregulated costimulatory and HLA molecules upon TLR-
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stimulation (Fig. S4B). Similarly, the HSPC-derived pDCs
showed a mature phenotype and secreted high amounts of
IFN-a and TNF-a (Fig. S4A–B). Moreover, when the DCs
were stimulated in the bulk of total cultured cells, high levels
of IL-12p70 and IFN-a could be detected, indicating that the
total bulk culture could potentially be used as a vaccine
(Fig. S4C).
In conclusion, these data demonstrate that using the two-
step culture, we can generate a higher frequency of well
differentiated, IL-12 producing BDCA1C mDCs, while the FST
Figure 1. Generation of high numbers of BDCA1C mDCs, BDCA3C mDCs and pDCs from HSPCs. G-CSF mobilized CD34C HSPCs (either freshly isolated or thawed) were
cultured for 14–20 d in Cellgro DC medium supplemented with 1 mM SR1, 2% HS and 50 mg/mL AA in a one- or two-step protocol. In the one-step protocol, HSPCs were
cultured for 14–20 d in the presence of Flt3L, SCF and TPO (FST), while in the two-step protocol, HSPCs were expanded for 7–13 d with FST, then washed and reseeded
in medium containing GM-CSF and IL-4 (G4) and subsequently cultured for seven additional days. (A) Schematic overview of the two different culture protocols, the FST
culture (one-step protocol) and G4 culture (two-step protocol). (B) Cumulative fold expansion of total cells at the end of 14–20 d culture, where cells were expanded for
7–9 d (ﬁlled circles) or 12–13 d (open circles), followed by 7 d differentiation. Each dot represents an independent donor, lines indicate the mean value (n D 11). (C–E)
After 14–20 d culture, the frequencies of BDCA1C mDCs, BDCA3C mDCs and pDCs were determined by ﬂow cytometry. (C) Representative plots showing percentage of
BDCA1C mDCs, BDCA3C mDCs and pDCs within total cultured cells. Gating strategy is depicted in Fig. S2. (D) The frequencies of BDCA1C mDCs, BDCA3C mDCs and pDCs
within total cultured cells of 9–11 different donors. (E) Numbers of BDCA1C mDCs, BDCA3C mDCs and pDCs generated from 1 £ 106 CD34C cells. (D–E) Each dot repre-
sents an independent donor, lines indicate the mean value (n D 9–11). (F–G) Surface expression of BDCA1, HLA-DR, CD11c and CD14 on HSPC-DCs in FST and G4 cultures
was determined by ﬂow cytometry. (F) Dot plots from one representative donor. (G) Mean ﬂuorescence intensity (MFI) of HLA-DR and CD11c within the BDCA1C mDC
population. Data are depicted as mean § SEM of seven independent donors. Statistical analysis was performed using paired student’s t-test. p < 0.05, p < 0.01,
p < 0.001.
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culture is most optimal for generation of high numbers of IFN-
a producing pDCs.
BDCA1C HSPC-DCs efﬁciently prime na€ıve MiHA-speciﬁc T
cells
After establishing the optimal culture conditions for generation
of HSPC-DC, we examined their T cell and NK cell stimulatory
capacity. To evaluate the capacity of HSPC-DCs in priming
na€ıve antigen-speciﬁc T cells, sorted HSPC-derived BDCA1C
mDCs and pDCs were matured, loaded with MiHA peptide
and co-cultured with autologous puriﬁed CD8C T cells from
MiHA-negative donors. For these assays, we used three HLA-
A2 restricted and hematopoietic-speciﬁc MiHAs named
HA129, UTA2–130 and HA8.31 At day 7, a clear population of
MiHA-speciﬁc CD8C T cells could be observed upon BDCA1C
mDC stimulation (Fig. 2A, Fig. S5), which efﬁciently expanded
upon an additional week of stimulation with MiHA-loaded
BDCA1C mDCs (Fig. 2A–B). After overnight peptide rechal-
lenge, BDCA1C mDC-primed MiHA-speciﬁc T cells upregu-
lated the activation marker CD137 and were highly positive for
both IFN-g and the degranulation marker CD107a (Fig. 2C).
In contrast, no MiHA-speciﬁc CD8C T cells could be detected
in pDC-stimulated cultures (Fig. 2D). These data demonstrate
that the HSPC-derived BDCA1C mDCs are highly effective in
priming and activating CD8C T cells from the na€ıve repertoire.
BDCA1C HSPC-DCs and pDCs possess superior capacity to
expand and activate CD8C Tem cells
Next, we assessed the capacity of the HSPC-DC, in comparison
to autologous monocyte-derived DCs (MoDCs), to expand and
activate effector memory CD8C T (Tem) cells. In these assays,
we used PBMCs (peripheral blood mononuclear cells) from
four patients with a hematological malignancy who developed
HA1-speciﬁc CD8C T cell responses after alloSCT, and stimu-
lated them for one week with TLR-matured HA1 peptide-
loaded HSPC-DCs or MoDCs, generated from unrelated third-
party HLA-A2CHA1¡ donors. Interestingly, HSPC-derived
BDCA1C mDCs and pDCs showed superior capacity to induce
expansion of MiHA-speciﬁc Tem cells, evident by higher fre-
quencies and absolute numbers of HA1-tetramerC CD8C T
cells as compared with MoDC stimulation (Fig. 3A–C). In three
out of four patients, the BDCA1C mDCs were more efﬁcient
than pDCs in boosting T cell expansion. These responses were
highly speciﬁc, as no expansion of HA1-tetramerC CD8C T
Figure 2. HSPC-derived BDCA1C mDCs efﬁciently prime and activate na€ıve MiHA-speciﬁc T cells. HSPC-DCs were generated as described in Fig. 1, and subsequently
BDCA1C mDCs were sorted from G4 culture and pDCs from FST culture. Next, BDCA1C mDCs were stimulated with R848 and Poly I:C (RPI:C) in the presence of GM-CSF
and IL-4, while pDCs were stimulated with R848 in the presence of IL-3. (A–B) Puriﬁed CD8C T cells from MiHA-negative HLA-A2C donors were cultured for two consecu-
tive weeks with autologous MiHA peptide-loaded TLR-matured BDCA1C mDCs. Cells were screened for the presence of MiHA-speciﬁc CD8C T cells using ﬂow cytometry
on days 7 and 14. Density plots (A) and absolute MiHA-speciﬁc CD8C T cell numbers (B). (C) BDCA1C mDC-primed and expanded MiHA-speciﬁc T cells of donor B were
overnight rechallenged with or without 5 mM HA1-peptide at day 14, followed by intracellular staining for CD137, IFN-g and CD107a. (D) Puriﬁed CD8C T cells from
MiHA-negative HLA-A2C donor were cultured for one week with MiHA-loaded TLR-matured pDCs. Presence of MiHA-speciﬁc CD8C T cells was determined by ﬂow cytom-
etry on day 7. (A, C–D) The numbers in the dot plots represent the percentage of tetramer-positive cells within CD3CCD8C T cells.
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Figure 3. HSPC-derived BDCA1C mDCs show superior capacity to expand and activate antigen-experienced CD8C Tem cells. HSPC-DCs were generated as described in
Fig. 1, and subsequently BDCA1C mDCs were sorted from G4 culture and pDCs from FST culture. Next, the BDCA1C mDCs, pDCs and autologous MoDCs were activated
with respective TLR-ligands as indicated in the ﬁgure, in the presence of GM-CSF and IL-4 (MoDCs and BDCA1C mDCs) or IL-3 (pDCs). Thereafter, TLR-matured HA-1 pep-
tide-loaded DCs were co-cultured for one week with patient PBMCs at a 1:0.1 ratio (PBMC:DC) (n D 4). The HSPC-DCs and MoDCs used for expansion of patient HA1-spe-
ciﬁc CD8C T cells were from unrelated third party donor apheresis products, as there was no apheresis material available of the corresponding transplant donors. The
frequency of HA1-speciﬁc CD8C T cells at day 0 was <0.02% in Pt. 1–3 and 0.61% in Pt. 4. (A) Density plots showing the percentage of HA1-speciﬁc CD8C T cells at day 7.
The numbers in the dot plots depict the percentage of positive cells within CD3CCD8C T cells. (B) Absolute HA1-speciﬁc CD8C T cell numbers after one week co-culture
with DCs. (C) Fold expansion of HA1-speciﬁc CD8C T cells, calculated by dividing the number of HA1-speciﬁc T cells at day 7 with the number of HA1-speciﬁc T cells at
day 0. (D) 7-d DC-stimulated PBMCs of Pt. 4 were rechallenged overnight with 5 mM HA1-peptide and subsequently stained intracellular for CD137 and IFN-g. As control,
a small portion of cultured cells from all conditions was pooled and cultured overnight without HA1-peptide (No peptide). Numbers in the dot plots indicate the percent-
age of IFN-gC CD8C T cells within CD3CCD8C T cells. Pt. D patient. N.d. D not determined.
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cells was seen with non-loaded DCs (Fig. 3A, Fig. S6A). Addi-
tionally, the expanded T cells exhibited strong effector func-
tionalities, as reﬂected by the high percentage of IFN-
gCCD137C CD8C T cells from patient four after overnight
HA1 peptide rechallenge (Fig. 3D). To explore their T cell stim-
ulatory capacity further, we stimulated established CTL clones
with peptide-loaded HSPC-DCs or MoDCs. Interestingly, the
pDCs showed better potency for boosting IFN-g production by
HA1 and CMV effector CTLs than mDCs or MoDCs (Fig. 4).
Furthermore, TLR-stimulated bulk of total culture HSPC-DCs
also efﬁciently activated HA1 and CMV effector CTLs
(Fig. S6B). No IFN-g secretion was observed in DC:T cell co-
cultures in the absence of HA1 or CMV peptide (Fig. S6B). In
summary, these data demonstrate the superior capacity of
HSPC-derived BDCA1C mDCs in expanding tumor-reactive
CD8C Tem cells, while the HSPC-derived pDCs appear to
exhibit stronger potency to induce effector functions of anti-
gen-experienced T cells.
HSPC-pDCs superiorly induce activation of cytolytic NK
cells
As there is accumulating evidence for the important role of
DC-mediated NK cell activation in antitumor immunity,32-35
we next assessed the NK cell stimulatory capacity of HSPC-
DCs. Therefore, NK cells were co-cultured with sorted alloge-
neic HSPC-derived BDCA1CmDCs or pDCs in the presence of
different DC maturation stimuli. After 40 h of co-culture, a DC
dose-dependent increase in CD69 expression on the NK cells
was observed, where TLR-matured BDCA1C mDCs and pDCs
induced the highest expression (Fig. 5A–B). In contrast, TRAIL
expression on NK cells was primarily induced by pDCs
(Fig. 5A, C), especially by CpG-A-activated pDCs. TRAIL-
expression induced by R848-activated pDCs varied between
donors, and was high in experiment 1 (Fig. 5A), but low in
experiments 2 and 3 (Fig. 5C). This may possibly have
correlated with the respective IFN-a secretion from the stimu-
lated pDCs, which varied in response to R848 (19.5 fg/pDC in
experiment 1, <0.1 fg/pDC in experiments 2–3), as studies
indicate that TRAIL upregulation on NK cells is dependent
upon signaling via type I IFN receptor.36-38 Interestingly, NK
cells co-cultured at a lower ratio with non-TLR activated pDCs
(in the presence of IL-3) also highly expressed TRAIL, despite
very limited IFN-a secretion by non-TLR activated pDCs
(<0.1 fg/pDC).
Importantly, NK-mediated cytotoxicity was greatly
enhanced following DC priming, in particular with CpG-A-
activated pDCs (Fig. 6). NK cells co-cultured with as few as 2%
pDCs (ratio 1:0.02) in the presence of CpG-A, killed over 88%
of the Daudi cells compared with <30% killing by non-primed
NK cells. In addition, correlating with the TRAIL expression,
we observed efﬁcient Daudi killing following coculture of NK
cells with IL-3-cultured pDCs. In control conditions, where NK
cells were cultured without DCs in the presence of the different
DC maturation stimuli, expression of CD69 and TRAIL
remained low and Daudi killing was also low (Figs. 5B–C, 6).
Furthermore, no Daudi killing was observed by DC:Daudi co-
cultures in the absence of NK cells (data not shown). These
ﬁndings show that HSPC-DCs can activate and potentiate cyto-
lytic capacity of NK cells, where in particular pDCs possess
superior capability for boosting NK tumor reactivity.
Discussion
Although alloSCT can be a curative therapy for patients with
hematological malignancies, high relapse rates remain the lead-
ing cause of treatment failure. DC vaccination using a combina-
tion of different DC subsets may be an attractive adjuvant
treatment to boost GVT immunity. We and others39 postulate
that vaccination with multiple DC subsets could not only
robustly activate tumor-antigen reactive T cells, but also
alloreactive NK cells, the two key effector populations involved
in tumor cell elimination post alloSCT. Previously, we reported
a novel protocol for the generation of BDCA1C mDCs,
BDCA3C mDCs and pDCs from CD34C HSPCs, using the aryl
hydrocarbon receptor antagonist SR1 in combination with
Flt3L, SCF, TPO and IL-6.24 Here, we developed an optimized
GMP-compliant culture protocol, where high amounts of
mDCs and pDCs can be generated from G-CSF mobilized
CD34C cells obtained from alloSCT donors. Notably, omission
of IL-6 from the culture, as well as supplementation with AA
and HS, had positive impact on ex vivo DC differentiation. Fur-
thermore, an additional differentiation boost at the end of the
culture, where GM-CSF and IL-4 were added instead of Flt3L,
SCF and TPO (named G4 culture) resulted in a higher frequen-
cies of BDCA1C mDCs with high CD11c expression. However,
this protocol was less ideal for pDC generation, as GM-CSF
and IL-4 inhibited pDC differentiation, as also described by
others.40 Therefore, we favored generation of HSPC-mDCs
using the G4 culture, and generation of HSPC-pDCs using the
FST culture. Cumulatively, these changes allow ex vivo genera-
tion of clinically relevant dosages of HSPC-derived BDCA1C
mDCs and pDCs which, importantly, produce high amounts of
IL-12 and IFN-a upon TLR stimulation. We envision that these
immunostimulatory HSPC-DC, presenting MiHAs and/or
Figure 4. HSPC-derived pDCs show superior capacity to induce IFN-g secretion by
CD8C Tem cells. HSPC-DCs were generated and activated as described in Fig. 3.
TLR-matured DCs were seeded in triplicate and loaded for 1 h with 1 mM HA1 or
CMV peptide at 37C. Next, without washing, CTLs speciﬁc for HA1 or CMV were
added at 1:1 ratio and co-cultured for 24 h. Concentrations of IFN-g were deter-
mined by ELISA. Results are depicted as mean§ SD of a representative experiment
(HA1 CTL: n D 2, CMV CTL: n D 1). Statistical analysis was performed by one-way
ANOVA, followed by Bonferroni post-hoc test p < 0.05, p < 0.01, p < 0.001.
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TAAs, might be a potent adjuvant therapy for patients with
hematological malignancies post alloSCT.
As this HSPC-DC vaccine could be suitable for pre-emptive
or therapeutic vaccination post alloSCT, we evaluated their
stimulatory capacity. Importantly, we observed DC-subset spe-
ciﬁc characteristics of our cultured HSPC-DC subsets similar to
what has been described in literature.8-10 Ex vivo-generated
BDCA1C mDCs were more efﬁcient in priming na€ıve T cells
and subsequent expansion of MiHA-speciﬁc Tem cells than
pDCs. These characteristics are likely related to the higher co-
stimulatory phenotype of BDCA1C mDCs and their secretion
of IL-12p70.8,11 Previously, we and others have demonstrated
that DC-induced MiHA-speciﬁc Tem cells have efﬁcient killing
capacity against malignant cells of hematopoietic origin
expressing the respective MiHA.41-44 Notably, HSPC-derived
pDCs were superior in inducing IFN-g secretion by Tem cells,
and additionally promoted superior NK cell activation and
cytotoxicity. CpG-A activated pDCs, secreting high levels of
IFN-a, showed the strongest NK cell activation. IFN-a is a
potent NK cell modulator, and is known to enhance both
TRAIL expression and cytolytic capacity of NK cells.36-38,45
Interestingly, we observed that non-TLR activated HSPC-pDCs
also induced high TRAIL expression and NK cell-mediated
cytotoxicity. In the presence of IL-3 alone, no IFN-a was
detectable in those co-cultures (data not shown). However,
studies indicate that cell-dependent contact with NK cells may
enhance the maturation and IFN-a secretion capacity of
pDCs.46 This may account for the reciprocal activation of NK
cells observed.
Nowadays, the majority of alloSCT patients receive hemato-
poietic stem cells obtained from leukapheresis products of (G-
CSF) mobilized donors.47 As the yield of CD34C cells is often
sufﬁcient for transplantation, it would be possible to cryo-
preserve  5% of the donor graft (i.e., max. 3 £ 109 total cells
or 25 £ 106 CD34C HSPCs) for eventual DC vaccine genera-
tion. Using the optimized HSPC-DC-generation protocol, the
FST culture would result in average in 180 £ 106 BDCA1C
mDCs and 160 £ 106 pDCs from 10 £ 106 G-CSF mobilized
CD34C HSPCs, and the G4 culture would result in average in
180 £ 106 BDCA1C mDCs from 10 £ 106 HSPCs. Those
achieved numbers are considerably higher than with the previ-
ously published protocol,24 and could be sufﬁcient for  9
Figure 5. HSPC-pDCs superiorly induce activation of cytolytic NK cells. HSPC-DCs were generated as described in Fig. 1, and subsequently BDCA1C mDCs were sorted
from G4 culture and pDCs from FST culture. Next, the different HSPC-DCs were seeded and medium was added containing respective TLR-ligands and cytokines as indi-
cated in the ﬁgure. Without washing, allogeneic NK cells were added to the DCs at 1:0.2, 1:0.05 or 1:0.02 ratio (NK:DC). As control, NK cells were cultured without DCs in
the absence (control D ctrl) or presence of the different DC maturation cocktails. By ﬂow cytometry, expression of CD69 and TRAIL on NK cells was determined after 40 h
co-culture. (A) Histograms depicting expression of CD69 and TRAIL on DC-primed NK cells of experiment 1 at a NK:DC ratio of 1:0.2. (B–C) The percentage and mean ﬂuo-
rescent intensity (MFI) of CD69 (B) and TRAIL (C) on NK cells of experiments 2 and 3 at a NK:DC ratio of 1:0.2, 1:0.05 or 1:0.02. (A–C) Data shown are from three indepen-
dent experiments using three different HSPC-DC and three different NK cell donors. NK cell purity was 97%, 87% and 97% for experiments 1, 2 and 3, respectively.
Exp. D Experiment.
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repetitive vaccinations. Importantly, by generating the DCs
from a portion of the donor stem cell graft, these vaccines are
obtained without extra apheresis burden for the alloSCT donor.
Moreover, during their differentiation, HSPC-DCs can be mod-
iﬁed to further augment their stimulatory capacity. For exam-
ple, immature DCs could be silenced for co-inhibitory
molecules such as PD-L1 and PD-L2, by transfection with small
interfering RNAs. We have previously demonstrated that PD-
L-silenced MoDCs show superior potential in activating
tumor-reactive T cells.48-51 Additionally, HSPC-DCs could be
transfected with mRNA of the tumor target antigen (MiHA or
TAA), to provide long-lasting presentation of multiple anti-
genic epitopes.49,52-54
Further pre-clinical studies are warranted to investigate
whether enrichment of the different DC subsets will be needed
or whether the whole bulk of cultured cells can be used as vac-
cine. Apart from the different DC subsets generated from the
CD34C HSPCs, the culture contained a heterogenous mixture
of monocytic and myelocytic cells (deﬁned by CD14, CD15,
CD11b and CD34 expression; Fig. S7), but not allogeneic T
cells nor B cells (data not shown). Of the total cultured cells,
»25% and »50% within the FST culture and G4 culture,
respectively, were HLA-DR negative cells (Fig. S7A–B), which
may potentially suppress DC-mediated activation of T cells and
NK cells. However, Haar et al. recently demonstrated that
HSPC-derived HLA-DR¡ cells obtained with their culture sys-
tem did not suppress T cell proliferation, but rather induced T
cell proliferation.55 Within the HLA-DR negative fraction, we
could identify a population of cells double positive for CD15
and CD11b (Fig. S7D–E), a phenotype associated with mye-
loid-derived suppressor cells.56 Since we observed these cells
primarily in the long (i.e., >19 d) G4 cultures (7–18% of total
cultured cells), we favor the shorter culture procedure
(i.e., <16 d), where the frequency of HLA-DR¡CD15CCD11bC
cells was <4% out of total cultured cells. Shorter culture proce-
dure is also more cost-effective and requires less handling.
It also remains to be investigated which vaccination and
TLR stimulation scheme is most optimal for HSPC-DC vacci-
nation. For repeated vaccinations, the HSPC-DCs will need to
be cryopreserved. Whether it would be better to cryopreserve,
the DCs before or after TLR maturation needs to be established.
At the same time, the optimal protocol for TLR stimulation, i.e.,
which GMP-grade TLR ligands and duration of stimulation,
will need to be investigated. Furthermore, there is accumulating
evidence that the different DC subsets potentiate each other’s
stimulatory capacity via cross-talk.19-23 For instance, Nierkens
et al. described that vaccination of mice with mDCs activated
in the presence of pDCs resulted in enhanced cross-priming
capacity of the mDCs and subsequently augmented antitumor
immune responses.19 Furthermore, Lou et al. demonstrated
that immunization of mice with a combination of activated
mDCs and pDCs resulted in increased levels of antigen-speciﬁc
CD8C T cells and facilitated better tumor clearance compared
with immunization with either DC subset alone.20 It could
therefore be favorable to stimulate and/or infuse the different
DC subsets simultaneously. However, it could also be more
beneﬁcial to harness the distinct features of the different
HSPC-DC subsets by independent vaccination with mDCs and
pDCs, by infusing the different DC subsets at different loca-
tions, and/or at different time-points.
In conclusion, we have developed a GMP-compliant culture
protocol where high numbers of different DC subsets, with
unique characteristics and functionalities, can be differentiated
from the alloSCT donor stem cell grafts. These HSPC-DC sub-
sets are highly potent stimulators of tumor-reactive T cells and
NK cells. Together, these ﬁndings indicate that vaccination
with HSPC-DCs may be an attractive adjuvant therapy post
alloSCT to boost GVT immunity.
Material and methods
Patient and donor material
For generation of HSPC-DCs and MoDCs, PBMCs were
obtained from leukapheresis material of G-CSF mobilized stem
cell donors. CD8C T cells used for priming assays were isolated
from the same material. For T cell expansion assays, PBMCs
were obtained from patients with hematological malignancies
who developed HA1-speciﬁc CD8C T cell responses following
alloSCT.57 Samples were collected 6–31 mo after alloSCT.
Patient (Pt) 1 and 2 did not receive additional donor lympho-
cyte infusion post-transplant, whereas Pt 3 and 4 received a
donor lymphocyte infusion 16 and 2 mo before the sample
date, respectively. Because no apheresis material of the corre-
Figure 6. HSPC-pDCs superiorly potentiate cytolytic capacity of NK cells. NK cells
were co-cultured with DCs for 40 h as described in Fig. 5. Subsequently, a 4 h ﬂow
cytometric cytotoxicity assay was performed, where Daudi tumor cells were added
at a NK:Daudi ratio of 1:0.5. The graphs depict percentage of speciﬁc killing
(mean § SD of triplicates), and was calculated as follows: 100 – ((absolute number
of viable CFSEC Daudi cells cocultured with NK cells/absolute number of viable
CFSEC Daudi cells cultured alone) £ 100). Data depicted are from the same two
experiments as are described in Fig. 5B–C. Exp. D Experiment.
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sponding transplant donors was available, HSPC-DCs and
MoDCs used for expansion of these patient-derived HA1-spe-
ciﬁc T cells were generated from allogeneic HLA-A2CHA1¡
donors (from a third party apheresis). For isolation of NK cells,
healthy donor buffy coats were obtained from Sanquin blood
bank. Cellular material was obtained in accordance with the
Declaration of Helsinki and institutional guidelines and regula-
tions (CMO 2013/064).
Ex vivo generation of HSPC-DCs and MoDCs
CD34C cells were isolated from G-CSF mobilized PBMCs using
anti-CD34 microbeads (Miltenyi Biotec, catalog# 130–046–
702). Purity and viability was evaluated by ﬂow cytometry.
CD34C HSPCs were either used directly for HSPC-DC genera-
tion, or cryopreserved in 50% HS (PAA Laboratories), 42.5%
IMDM (GIBCO Invitrogen, catalog# 21980–032) and 7.5%
DMSO (Sigma-Aldrich) and thawed at a later time-point for
HSPC-DC generation. To generate HSPC-DCs, CD34C HSPCs
were cultured for 14–20 d in Cellgro DC medium (GMP-com-
pliant, Cellgenix, catalog# 20801–0500), supplemented with
1 mM SR1 (Cellagen Technology, catalog# C7710–5) as
described previously.24 The medium was additionally supple-
mented with 2% HS and 50 mg/mL AA (Centrafarm) during
the entire culture period. During the ﬁrst 7 d of culture, the
medium was supplemented with Flt3L, SCF and TPO, 100 ng/
mL each (all from Immunotools, catalog# 11343305, 11343328
and 11344865, respectively). For the remaining culture period,
the concentrations of SCF and TPO were reduced to 50 ng/mL.
Alternatively, HSPC-DCs were generated in a two-step proto-
col: after 7–13 d expansion as described above, cells were har-
vested, washed and reseeded in Cellgro DC medium containing
800 IU/mL GM-CSF and 500 IU/mL IL-4 (both from Immuno-
tools, catalog# 11343125 and 11340048, respectively) and cul-
tured for seven additional days. At day 0, the CD34C HSPCs
were seeded at 1 £ 105–2 £ 105 cells/mL, while after day 7 their
density was adjusted to 1 £ 106–1.5 £ 106 cells/mL every 2–3 d
with growth factor-supplemented medium. Total number of
viable cells was determined by trypan blue exclusion counting
at ﬁxed timepoints during the culture period. At the end of the
culture, samples were taken for ﬂow cytometric analysis, and
absolute numbers of DCs were calculated by multiplying the
frequency of DCs with the absolute number of total cells gener-
ated from 1 £ 106 CD34C cells. For functional experiments,
BDCA1C mDCs and pDCs were sorted from HSPC-DC cul-
tures by labeling the cells with anti-BDCA1 (clone L161) and
anti-CD123 (clone 6H6) antibodies (both from Biolegend),
respectively, followed by ﬂuorescence-activated cell sorting
(FACS) using the FACS Aria (BD Biosciences). The sorted DC
subsets were in all cases used directly (fresh) for functional
assays, except in assays described in Fig. 2A–B, where cryopre-
served/thawed DCs were used for day 7 re-stimulation of
primed MiHA-speciﬁc T cells.
MoDCs were generated in 7 d from plastic adherent mono-
cytes in Cellgro DC medium supplemented with 2% HS, 800
IU/mL GM-CSF and 500 IU/mL IL-4, as described
previously.58
DC maturation and cytokine release
Sorted HSPC-DC subsets were resuspended in IMDM supple-
mented with 10% fetal calf serum (FCS, Integro) and matured
overnight with TLR-ligands. pDCs were stimulated with
3.2 mg/mL CpG-A (ODN 2216) or 5 mg/mL R848 (Resiqui-
mod; both from Enzo Life Sciences, catalog# ALX-746–005 and
ALX-420–038, respectively) in medium supplemented with IL-
3 (10 ng/mL, Immunotools, catalog# 11340035), while
BDCA1C mDCs were stimulated with a combination of 5 mg/
mL R848 and 20 mg/mL Poly I:C (Polyinosinic:polycytidylic
acid, Sigma-Aldrich, catalog# P0913), referred to as RPI:C, in
the presence of GM-CSF (800 IU/mL) and IL-4 (500 IU/mL).
MoDCs were matured with RPI:C or conventional cytokine
mixture (cytomix) containing 5 ng/mL IL-1b, 15 ng/mL IL-6,
20 ng/mL TNF-a and 1 mg/mL PGE2, as described previ-
ously.51 Cell culture supernatants were analyzed with ELISA
for IFN-a (pan-speciﬁc, MabTech, catalog# 3425–1H-20), IL-
12p70 (eBioscience, catalog# 14–8129 (standard), 16–8126
(coating Ab) and 13–7129 (detection Ab)) and TNF-a (San-
quin, catalog# M9323) levels, according to manufacturer’s
instructions.
Flow cytometry
Cells were pre-incubated on ice with total human IgG
(Nanogam, Sanquin) to block Fc-receptors, and subse-
quently stained with appropriate antibody combinations.
HSPC-DCs were phenotyped with anti-BDCA1/CD1c (clone
L161), anti-BDCA2/CD303 (clone 201A), anti-BDCA3/
CD141 (clone M80), anti-BDCA4/CD304 (clone 12C2),
anti-DNGR1/Clec9A/CD370 (clone 8F9), anti-HLA-ABC
(clone W6/32), anti-CD11c (clone 3.9), anti-CD15 (clone
W6D3), anti-CD80 (2D10), anti-CD83 (clone HB15e), anti-
CD86 (clone IT2.2), anti-CD123 (clone 6H6, all from Biole-
gend), anti-HLA-DR (clone Immu357), anti-CD11b (clone
Bear1), anti-CD14 (clone RMO52), anti-CD34 (clone 581,
all from Beckman Coulter), anti-PD-L1/CD274 (clone
MIH1) and anti-CD123 (clone 7G3, both from BD Biosci-
ence). NK cell activation was determined with anti-TRAIL/
CD253 (clone RIK-2), anti-CD3 (clone UCHT1), anti-CD56
(clone HCD56) and anti-CD69 (clone FN50, all from Biole-
gend). Relevant isotype control antibodies were used from
Biolegend. MiHA-speciﬁc T cells were detected by staining
with anti-CD3 (clone UCHT1, Biolegend), anti-CD8C (clone
3B5, Invitrogen) and peptide/MHC-tetramers (HA1.A2:
VLHDDLLEA,29 UTA2–1.A2: QLLNSVLTL,30 HA8.A2:
RTLDKVLEV31), as described previously.42,51,59 Acquisition
and data analysis was performed with a Gallios ﬂow cytom-
eter and Kaluza software (both from Beckman Coulter).
Dead cells were excluded using Sytox blue (Invitrogen, cata-
log# S34857), 7AAD (Sigma, catalog# A9400) or eFluor780
ﬁxable viability dye (eBioscience, catalog# 65–0865–14).
MiHA-speciﬁc T cell assays
In T cell priming experiments, CD8C T cells were isolated from
MiHA-negative HLA-A2C G-CSF mobilized PBMCs from
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male donors using CD8Cmicrobeads (Miltenyi Biotec, catalog#
130–045–201). For HA1-speciﬁc T cell expansion assays,
PBMC samples obtained from alloSCT patients containing
HA1-reactive CD8C T cells were used. For these assays, HSPC-
DCs and MoDCs were generated from HLA-A2C MiHA¡
donors. Matured MoDCs, HSPC-derived BDCA1C mDCs and
HSPC-derived pDCs were harvested, loaded with 5 mM
MiHA-peptide (HA1, UTA2–1 or HA8, from LUMC-IHB pep-
tide facility, the Netherlands or ThinkPeptides), washed and
subsequently co-cultured with the isolated CD8C T cells or
patient PBMCs in IMDM/10%HS at a ratio of 1:0.2 to 1:0.1 (T
cell/PBMC:DC), as described previously.42,51 For priming
assays, a minimum of 9 £ 106 CD8C T cells were used per DC
subset. At days 2 and 5, IL-2 (50 U/mL, Proleukin, Chiron)
and IL-15 (5 ng/mL, Immunotools, catalog# 11340155) were
added to the co-cultures. At day 7, cells were counted and ana-
lyzed by ﬂow cytometry, and when indicated, re-stimulated
with the respective DC subset. For re-stimulation, cryopre-
served/thawed DCs were used. To determine functionality,
DC-stimulated T cells were rechallenged overnight with 5 mM
MiHA peptide in the presence of anti-CD107a (BD Bioscience,
clone H4A3), followed by an intracellular staining for IFN-g
(BD Bioscience, clone B27) and CD137 (Biolegend, clone 4–
1BB), as described previously.42,51
CTL activation
CD8C T cell clones speciﬁc for HA1.A2 and CMV.A2 were iso-
lated from patient 4 and a healthy donor, respectively, and
expanded following protocols described previously.60 Mature
DCs were harvested, washed, seeded in triplicate in 96-well
round-bottom plate (Corning Costar, catalog# 3799, 104 DCs/
well) in IMDM/10%FCS and loaded with 1 mM HA1 or CMV
(NLVPMVATV,61 LUMC-IHB peptide facility) peptide. After
1 h incubation at 37C, HA1- or CMV-speciﬁc CTLs were
added at 1:1 ratio. After 24 h co-incubation, supernatant was
harvested and IFN-g production was measured by ELISA
(Thermo Scientiﬁc, catalog# M700A (coating Ab) and M701B
(detection Ab)).
NK-DC co-culture
NK cells were isolated using the untouched NK cell isola-
tion kit (Miltenyi Biotec, 130–092–657), resulting in >87%
NK cell purity (CD56CCD3¡ cells). HSPC-derived BDCA1C
mDCs or pDCs were resuspended in IMDM/10%FCS,
whereupon 10 £ 103, 2.5 £ 103 or 1 £ 103 cells were
seeded per well in 96-well round-bottom plates. Subse-
quently, BDCA1C mDCs were matured using GM-CSF/IL-4
or GM-CSF/IL-4/RPI:C, while pDCs were matured with IL-
3, IL-3/CpG-A or IL-3/R848, as described above. Next, 5 £
104 freshly isolated allogeneic NK cells were added, result-
ing in NK:DC ratios of 1:0.2, 1:0.05 or 1:0.02. After 40 h
co-culture, CD69 and TRAIL expression on NK cells was
evaluated by ﬂow cytometry. Besides, a 4 h cytotoxicity
assay was performed with 1 mM CFSE-labeled62 Daudi
tumor cells in the presence/absence of 40-h DC-primed NK
cells at a NK:Daudi ratio of 1:0.2. Subsequently, cells were
harvested and stained with 7AAD, followed by
quantiﬁcation of viable Daudi cells using the FC500 ﬂow
cytometer (Beckman Coulter). The percentage of speciﬁc
killing was calculated as follows: 100 – ((absolute number
of viable CFSEC Daudi cells cocultured with NK cells/abso-
lute number of viable CFSEC Daudi cells cultured alone) £
100).62-64
Statistics
Statistical analysis was performed using GraphPad Prism 5.0.
Student’s t-test or one-way ANOVA, followed by Bonferroni
post-hoc test, was used as indicated. p-values <0.05 were con-
sidered signiﬁcant.
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